主页 > 医药科学 >
【medical-news】匹格列酮可以预防冠状动脉支架内
30 April 2007
MedWire News: Pioglitazone may represent a novel therapeutic option for targeting in-stent restenosis in nondiabetic patients with the metabolic syndrome, Japanese researchers suggest.
Masanobu Kawakami and colleagues from the Jichi Medical University in Saitama City have shown that pioglitazone, a novel insulin-sensitizing thiazolidinedione, reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with the metabolic syndrome.
The researchers randomly assigned 28 nondiabetic patients with the metabolic syndrome to 6 months of treatment with 30 mg/day of pioglitazone or standard medications only (control group) after the implantation of a bare-metal stent using intravascular ultrasound (IVUS).
After 6 months, insulin resistance was significantly lower in patients treated with pioglitazone than in controls, as indicated by lower immunoreactive insulin levels (67.1 vs 151.9 μU/ml, p=0.027). They also had less visceral fat accumulation (-32.8 vs -7 cm2), as measured by abdominal computerized tomography.
There were no significant differences in plasma glucose levels, glycosylated haemoglobin A1c, or lipid profiles, between the two groups, either before or after treatment.
Patients in the pioglitazone group also showed a reduced intimal index (13% vs 21%, p=0.033) and intimal area (1.28 vs 1.90 mm2, p=0.84) compared with patients in the control group.
Kawakami et al conclude in the American Heart Journal: “This is the fist randomized, prospective IVUS study demonstrating that pioglitazone reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with the metabolic syndrome.”
They suggest: “Our results indicated that reduction of neointimal hyperplasia by pioglitazone in nondiabetic patients with the metabolic syndrome is likely due to the improvement of insulin resistance.”
Am Heart J 2007; 153: 762.e1-762.e7
http://www.incirculation.net/NewsItem/Pioglitazone-shows-potential-for-instent-restenosi.aspx 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 Pioglitazone shows potential for in-stent restenosis prevention
匹格列酮可以预防冠状动脉支架内再狭宰
30 April 2007
2007年4月30日
MedWire News: Pioglitazone may represent a novel therapeutic option for targeting in-stent restenosis in nondiabetic patients with the metabolic syndrome, Japanese researchers suggest.
Medwire新闻: 日本研究人员表示，对于非糖尿病的代谢综合征患者，匹格列酮或许代表了一种治疗血管支架再狭窄的新颖选择
Masanobu Kawakami and colleagues from the Jichi Medical University in Saitama City have shown that pioglitazone, a novel insulin-sensitizing thiazolidinedione, reduces neointimal hyperplasia after coronary stenting in nondiabetic patients with the metabolic syndrome.
来自Saitama市Jichi医科大学的Masanobu Kawakami和他的的同事们都已表明，匹格列酮是一种新型的噻唑烷二酮类胰岛素增敏剂, 在非糖尿病的代谢综合征患者冠脉支架植入后，能降低血管内膜增生。
The researchers randomly assigned 28 nondiabetic patients with the metabolic syndrome to 6 months of treatment with 30 mg/day of pioglitazone or standard medications only (control group) after the implantation of a bare-metal stent using intravascular ultrasound (IVUS).
研究者随机分配28名非糖尿病的代谢综合征患者进行治疗，用匹格列酮30毫克/日，连续6个月；对照组采用标准药物,也连续6个月。植入裸金属支架后血管内超声检查.
After 6 months, insulin resistance was significantly lower in patients treated with pioglitazone than in controls, as indicated by lower immunoreactive insulin levels (67.1 vs 151.9 μU/ml, p=0.027). They also had less visceral fat accumulation (-32.8 vs -7 cm2), as measured by abdominal computerized tomography.
在6个月后, 匹格列酮（治疗组）胰岛素抗较对照组显著降低，也表明免疫反应性胰岛素水平较低(67.1vs 151.9万/毫升,p=0.027). 通过腹部CT检查，他们内脏脂肪堆积较少 (-32.8vs -7cm2)。
There were no significant differences in plasma glucose levels, glycosylated haemoglobin A1c, or lipid profiles, between the two groups, either before or after treatment.
（结果显示），在治疗前后，2组患者的血糖、糖化血红蛋白A1c或血脂无显著性差异。
Patients in the pioglitazone group also showed a reduced intimal index (13% vs 21%, p=0.033) and intimal area (1.28 vs 1.90 mm2, p=0.84) compared with patients in the control group.
匹格列酮组患者与对照组患者相比，内膜指数呈现减少(13%vs21%, P=0.033)和内膜面积也呈现减少(1.28vs 1.90mm2,p=0.84)
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-18 12:57
医学,生命科学网